Structure Therapeutics (NASDAQ:GPCR) Stock Rating Upgraded by Wall Street Zen

Structure Therapeutics (NASDAQ:GPCR) was upgraded by Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Monday.

A number of other brokerages have also commented on GPCR. Citizens Jmp cut their price target on Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating for the company in a report on Friday, August 7th. Canaccord Genuity Group set a $111.00 price objective on shares of Structure Therapeutics in a research note on Friday, August 7th. HC Wainwright dropped their target price on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a research report on Thursday, June 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Friday, July 17th. Finally, Citigroup reissued a “market outperform” rating on shares of Structure Therapeutics in a report on Friday, August 7th. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $110.91.

Structure Therapeutics Stock Performance

Shares of NASDAQ:GPCR opened at $53.53 on Monday. The stock’s 50-day moving average is $49.78 and its 200-day moving average is $52.13. The company has a market cap of $3.73 billion, a P/E ratio of -53.53 and a beta of -1.43. Structure Therapeutics has a 52-week low of $18.26 and a 52-week high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, equities analysts predict that Structure Therapeutics will post -1.84 EPS for the current year.

Institutional Trading of Structure Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of GPCR. Geode Capital Management LLC increased its holdings in Structure Therapeutics by 18.5% in the 2nd quarter. Geode Capital Management LLC now owns 54,181 shares of the company’s stock valued at $1,124,000 after buying an additional 8,444 shares during the period. Invesco Ltd. lifted its holdings in shares of Structure Therapeutics by 7.6% during the 2nd quarter. Invesco Ltd. now owns 424,548 shares of the company’s stock worth $8,805,000 after acquiring an additional 30,162 shares during the period. Marshall Wace LLP lifted its holdings in shares of Structure Therapeutics by 474.9% during the 2nd quarter. Marshall Wace LLP now owns 176,060 shares of the company’s stock worth $3,651,000 after acquiring an additional 145,434 shares during the period. Jump Financial LLC boosted its position in shares of Structure Therapeutics by 105.9% during the 2nd quarter. Jump Financial LLC now owns 63,234 shares of the company’s stock valued at $1,311,000 after acquiring an additional 32,524 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Structure Therapeutics during the 2nd quarter valued at about $3,480,000. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.